Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
All entries in multiple solid tumors
- New trial
Multiple solid tumors
Phase 1 PF-08046033 GPNMB-targeted antibody-drug conjugate delivers auristatin tubulin payload.
This first-in-human, open-label Phase 1 trial from Pfizer tests PF-08046033 as IV monotherapy in adults with metastatic/unresectable, progressive solid tumors, starting with dose escalation (multiple ascending dose…
NCT07519655 First-in-human - New trial
Multiple solid tumors
Phase 1/1b RGT-490 mutant-selective PI3Kα inhibitor in PIK3CA-mutant solid tumors.
This first-in-human, open-label Phase 1/1b study tests RGT-490, an oral small molecule designed as a mutant-selective PI3Kα (PIK3CA) inhibitor, aiming to suppress oncogenic PI3K pathway signaling while potentially…
NCT07524322 First-in-human - New trial
Multiple solid tumors
Phase 1 KIVU-107 PTK7-targeted antibody-drug conjugate in advanced solid tumors
This first-in-human, open-label Phase 1 study (KIVU-107-01) from Kivu Bioscience evaluates KIVU-107, a PTK7-directed antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload to PTK7-expressing tumor…
NCT07229313 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b BG-C0979 ADAM9-targeted ADC with Topo1 inhibitor payload ± tislelizumab
This first-in-human, multicenter, open-label Phase 1a/1b study tests BG-C0979, an ADAM9-targeted antibody-drug conjugate (ADC) delivering a DNA topoisomerase I (Topo1) inhibitor payload, sponsored by BeOne Medicines…
NCT07414836 First-in-human - New trial
Multiple solid tumors
Phase 1b/2 ASP546C CLDN18.2-targeted ADC with topoisomerase I inhibitor payload
Astellas Pharma Global Development is running this Phase 1b/2, open-label, multicohort study to define a tolerable, active dose and characterize safety/PK plus preliminary efficacy of ASP546C. ASP546C is an…
NCT07488676 Exploratory - New trial
Multiple solid tumors
Phase 1 IDE574 dual KAT6/KAT7 lysine acetyltransferase inhibitor ± fulvestrant (ER degrader)
This first-in-human, open-label, multicenter Phase 1 study evaluates IDE574 (oral small-molecule dual inhibitor of the epigenetic writer enzymes KAT6 and KAT7) from IDEAYA Biosciences, as monotherapy dose escalation…
NCT07540572 First-in-human - New trial
Multiple solid tumors
Phase 1 DISP-10 DV-10 oncolytic adenovirus + BCMA-targeted CAR T in GI cancers
This Phase 1, multicenter, open-label study from Dispatch Biotherapeutics tests DISP-10, a combination of DV-10 (an adenovirus-based tumor-targeted viral therapy intended to inflame tumors and/or introduce antigenic…
NCT07544589 First-in-human - New trial
Multiple solid tumors
Phase 1/2a CKD-703 trial tests c-Met–targeting MMAE microtubule-inhibitor ADC in solid tumors/NSCLC.
This first-in-human, multicenter, open-label Phase 1/2a study evaluates CKD-703, an antibody-drug conjugate from Chong Kun Dang Pharmaceutical (CKD Pharm) that uses a c-Met–binding monoclonal antibody to deliver…
NCT07439094 First-in-human - New trial
Multiple solid tumors
Phase 1a/1b GTB-5550 B7-H3–targeted TriKE NK-cell engager (CD16 + IL-15)
This first-in-human Phase 1a/1b, open-label, non-randomized basket study evaluates GTB-5550, a camelid nanobody tri-specific killer engager (TriKE) designed to activate and expand endogenous NK cells while directing…
NCT07541573 First-in-human - Trial result Spotlight
Multiple solid tumors
Zedoresertib (WEE1) + Lunresertib (PKMYT1) Shows Early Tumor Shrinkage in CCNE1/FBXW7-Altered Solid Tumors (notably ovarian)
Zedoresertib is an oral, selective WEE1 inhibitor and lunresertib is an oral, selective PKMYT1 inhibitor; dual checkpoint abrogation is designed to force premature mitotic entry under replication stress, driving…
NCT04855656 - Trial result Spotlight
Multiple solid tumors
Elisrasib (D3S-001) GDP-bound KRAS G12C inhibitor drives 62% ORR in mCRC with cetuximab—and 68% ORR as monotherapy in PDAC
Elisrasib (D3S-001) is an oral, next-generation KRAS G12C inhibitor engineered to bind the GDP-bound state and resist growth factor–driven nucleotide exchange; in KRAS G12C–mutant mCRC it was also combined with…
NCT05410145 - Trial result
Multiple solid tumors
BGB-24714 (SMAC mimetic/IAP antagonist) shows no MTD; adds cCRT response signal but chemo-combo activity mixed
BGB-24714 is a selective SMAC mimetic that antagonizes inhibitor-of-apoptosis proteins (IAPs), aiming to restore apoptosis and potentially sensitize tumors to chemotherapy or concurrent chemoradiotherapy (cCRT). In…
NCT05381909 - Trial result
Multiple solid tumors
AU409 transcription regulator (TATA-box modulation) shows 11% PR and multi-month disease control in pretreated HCC
AU409 is a first-in-class oral small molecule designed to modulate transcription at TATA-box regulatory elements, evaluated as monotherapy across two ongoing Phase 1 dose-escalation studies in advanced solid tumors…
NCT05791448 - Trial result
Multiple solid tumors
SynKIR-110 (mesothelin KIR-CAR/DAP12) shows early tumor shrinkage with low-grade CRS in refractory solid tumors
SynKIR-110 is an autologous mesothelin (MSLN)-targeted KIR-CAR T-cell therapy engineered to signal via the KIR/DAP12 multichain immune-receptor module (vs conventional CD3ζ CAR designs), aiming to reduce exhaustion…
NCT05568680 - Trial result
Multiple solid tumors
Tolododekin alfa (ANK-101) anchored IL-12 drives CD8+ influx—but M-MDSC expansion tracks with progression
Tolododekin alfa (ANK-101) is a first-in-class, aluminum hydroxide–anchored IL-12 cytokine designed for prolonged intratumoral retention after intratumoral injection. In the Phase 1 NCT06171750 correlative cohort…
NCT06171750 - Trial result
Multiple solid tumors
PLN-101095 (dual αvβ8/αvβ1 integrin; TGF-β activation blocker) + pembrolizumab delivers 40% iRECIST responses in ICI-secondary–refractory solid tumors
PLN-101095 is a first-in-class oral small-molecule dual αvβ8/αvβ1 integrin inhibitor intended to block latent TGF-β activation in the tumor microenvironment and potentially re-sensitize tumors to PD-1 blockade; it…
NCT06270706 - Trial result
Multiple solid tumors
SGR-3515 Wee1/Myt1 dual inhibitor shows manageable G3/4 AEs and 78% stable disease at 100–135mg in heavily pretreated solid tumors
SGR-3515 is an oral small-molecule dual inhibitor of the cell-cycle checkpoint kinases Wee1 and Myt1, designed to force CDK1 activation and disrupt G2/M control (synthetic-lethal rationale), and is being tested in…
NCT06463340 - Trial result
Multiple solid tumors
M3T01 (anti-FasL) Shows 60% Stable Disease and Clean Early Safety in Refractory Solid Tumors
M3T01 is a fully human IgG4/kappa monoclonal antibody that blocks Fas ligand (FasL), aiming to prevent FasL-mediated apoptosis of tumor-reactive T cells and potentially improve intratumoral T-cell infiltration. In an…
NCT06719362 - New trial Spotlight
Multiple solid tumors
Phase 1a/1b BMS-986504 MTA-cooperative PRMT5 inhibitor combo basket in MTAP-deleted tumors.
This Phase 1a/1b, disease-specific basket study tests BMS-986504 (navlimetostat), an MTA-cooperative PRMT5 inhibitor designed to exploit the MTAP-deletion/MTA accumulation vulnerability, in combination with standard…
NCT07532902 Exploratory - New trial
Multiple solid tumors
Phase 1 E303 Nectin-4–targeting antibody-drug conjugate in refractory solid tumors.
This first-in-human, open-label, multicenter Phase 1 study evaluates E303 (also referenced as SBE303), a Nectin-4–targeting antibody-drug conjugate (ADC) being developed by Samsung Bioepis. The trial uses sequential…
NCT07524348 First-in-human - New trial Spotlight
Multiple solid tumors
Phase 1a/1b DB-1317 (ADAM9-directed Topo-I ADC) in advanced solid tumors (GI-leaning)
DualityBio’s first-in-human DB-1317 is Q3W, with accelerated titration/BOIN escalation then expansion in GI-heavy tumors (gastric, CRC, PDAC). GI cancers still depend on chemo with few durable targets; ADAM9…
NCT07141706 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I BL-M05D1 CLDN18.2-directed Topo-I ADC (PDAC, biliary, G/GEJ & others)
SystImmune’s first-in-human study assesses safety/PK/efficacy of BL-M05D1 (IV Q3W) in CLDN18.2-expressing tumors, including PDAC, biliary tract cancer, and gastric/GEJ adenocarcinoma. Builds on CLDN18.2 momentum with…
NCT07021066 First-in-human - New trial
Multiple solid tumors
Phase II eVOLVE-02: volrustomig (MEDI5752; PD-1/CTLA-4 bispecific) ± combinations in advanced tumors (incl. HNSCC, cervical)
Academic sites with AstraZeneca are testing volrustomig (MEDI5752) as monotherapy and in volrustomig-based combinations (e.g., carboplatin/paclitaxel, cisplatin/5-FU) across tumor-specific sub-studies. CTLA-4/PD-1…
NCT06535607 Exploratory - New trial
Multiple solid tumors
Phase I SC-CAR.GPC3xIL15.21 pediatric/AYA CAR-T for GPC3+ non-CNS solid tumors (incl. HCC)
Seattle Children’s runs a first-in-human, single-infusion CAR-T armed with IL-15/21 plus an inducible safety switch for GPC3-positive tumors. Pediatric/AYA liver and other GPC3+ cancers (neuroblastoma) have sparse…
NCT07148050 First-in-human - New trial
Multiple solid tumors
Phase Ib IMA203 PRAME TCR-T + mRNA-4203 PRAME vaccine in melanoma/sarcoma
Immatics trials a first-in-human combo to amplify PRAME-specific T cells by pairing TCR-T with a PRAME mRNA vaccine. Post-IO melanoma needs deeper durability beyond ipi/nivo/TIL; synchronized vaccination may sustain…
NCT06946225 First-in-human - New trial Spotlight
Multiple solid tumors
Phase I study of AUBE00, an oral KRAS-targeting agent in solid tumors
This first-in-human Phase I study evaluates safety, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors harboring KRAS…
NCT07030959 First-in-human - New trial
Multiple solid tumors
Phase 1/2a VBC101: EGFR and cMET targeted bispecific antibody drug conjugate
This multicenter, open-label, multiple-dose first-in-human trial by VelaVigo Bio Inc evaluates VBC101 using an accelerated titration in Phase 1 dose escalation with a BOIN design and backfill cohorts to define the…
NCT07136779 First-in-human - New trial
Multiple solid tumors
Phase 1/2 TER-2013 (undisclosed target) trial in AKT/PI3K/PTEN-altered solid tumors
This open-label, multicenter study evaluates safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of lysine covalently binding small molecule TER-2013 (that may attack TRIP13…
NCT07109726 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2 OBI-902 TROP-2 antibody-drug conjugate trial in advanced solid tumors
This trial is designed to evaluate the safety, pharmacokinetics, and clinical activity of OBI-902 as dose-finding monotherapy in a phase 1 setting and at an optimized dose in phase 2 expansion cohorts. It includes…
NCT07124117 First-in-human - New trial
Multiple solid tumors
Phase 1 Trial of CYTALUX™ (Pafolacianine) Folate Receptor-Targeted Intraoperative Imaging Agent.
This Phase 1 open-label trial by Cedars-Sinai Medical Center is evaluating the feasibility of using CYTALUX™ (pafolacianine), a folate receptor directed fluorescent imaging agent, in adults with gastric, esophageal,…
NCT07124351 Exploratory
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.